AU2018290983B2 - Methods of treating heart failure with cardiac sarcomere activators - Google Patents

Methods of treating heart failure with cardiac sarcomere activators Download PDF

Info

Publication number
AU2018290983B2
AU2018290983B2 AU2018290983A AU2018290983A AU2018290983B2 AU 2018290983 B2 AU2018290983 B2 AU 2018290983B2 AU 2018290983 A AU2018290983 A AU 2018290983A AU 2018290983 A AU2018290983 A AU 2018290983A AU 2018290983 B2 AU2018290983 B2 AU 2018290983B2
Authority
AU
Australia
Prior art keywords
dose
subject
csa
plasma concentration
initial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018290983A
Other languages
English (en)
Other versions
AU2018290983A1 (en
Inventor
Narimon HONARPOUR
Fady Malik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Cytokinetics Inc
Original Assignee
Amgen Inc
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Cytokinetics Inc filed Critical Amgen Inc
Publication of AU2018290983A1 publication Critical patent/AU2018290983A1/en
Application granted granted Critical
Publication of AU2018290983B2 publication Critical patent/AU2018290983B2/en
Priority to AU2024200991A priority Critical patent/AU2024200991B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2018290983A 2017-06-30 2018-06-29 Methods of treating heart failure with cardiac sarcomere activators Active AU2018290983B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024200991A AU2024200991B2 (en) 2017-06-30 2024-02-15 Methods of treating heart failure with cardiac sarcomere activators

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762527983P 2017-06-30 2017-06-30
US62/527,983 2017-06-30
PCT/US2018/040181 WO2019006235A1 (en) 2017-06-30 2018-06-29 METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024200991A Division AU2024200991B2 (en) 2017-06-30 2024-02-15 Methods of treating heart failure with cardiac sarcomere activators

Publications (2)

Publication Number Publication Date
AU2018290983A1 AU2018290983A1 (en) 2020-01-23
AU2018290983B2 true AU2018290983B2 (en) 2023-11-23

Family

ID=63013097

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018290983A Active AU2018290983B2 (en) 2017-06-30 2018-06-29 Methods of treating heart failure with cardiac sarcomere activators
AU2024200991A Active AU2024200991B2 (en) 2017-06-30 2024-02-15 Methods of treating heart failure with cardiac sarcomere activators

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024200991A Active AU2024200991B2 (en) 2017-06-30 2024-02-15 Methods of treating heart failure with cardiac sarcomere activators

Country Status (22)

Country Link
US (4) US11576910B2 (enExample)
EP (2) EP4512470A3 (enExample)
JP (3) JP2020526483A (enExample)
CN (1) CN110996953A (enExample)
AU (2) AU2018290983B2 (enExample)
BR (1) BR112019028046A2 (enExample)
CA (1) CA3068588A1 (enExample)
DK (1) DK3645002T3 (enExample)
ES (1) ES3008457T3 (enExample)
FI (1) FI3645002T3 (enExample)
HR (1) HRP20241729T1 (enExample)
HU (1) HUE069805T2 (enExample)
LT (1) LT3645002T (enExample)
MA (1) MA49508B1 (enExample)
MD (1) MD3645002T2 (enExample)
MX (2) MX2020000190A (enExample)
PL (1) PL3645002T3 (enExample)
PT (1) PT3645002T (enExample)
RS (1) RS66581B1 (enExample)
SI (1) SI3645002T1 (enExample)
SM (1) SMT202500067T1 (enExample)
WO (1) WO2019006235A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014240049C1 (en) 2013-03-14 2019-03-07 Amgen Inc. Heterocyclic compounds and their uses
US11040956B2 (en) 2017-06-30 2021-06-22 Amgen Inc. Synthesis of omecamtiv mecarbil
LT3645002T (lt) 2017-06-30 2025-02-10 Amgen Inc. Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais
HUE052049T2 (hu) 2018-07-09 2021-04-28 Fis Fabbrica Italiana Sintetici Spa Kristályos 2-fluor-3-nitrotoluol és eljárás annak elõállítására
JP2021534138A (ja) 2018-08-17 2021-12-09 アムジエン・インコーポレーテツド オメカムチブメカルビルの塩及び結晶形態
CA3138080A1 (en) * 2019-05-19 2020-11-26 Jean-Francois TAMBY Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl) n-(isoxazol-3-yl)piperidine-1-carboxamid
CA3168513A1 (en) * 2020-02-10 2021-08-19 Amgen Inc. Omecamtiv mecarbil tablet
IL298885A (en) * 2020-06-15 2023-02-01 Myokardia Inc Treatment of atrial function
TW202233189A (zh) * 2020-11-12 2022-09-01 美商安進公司 藉由投與奧美卡替莫卡必爾治療心臟衰竭之方法
CN116710139A (zh) * 2020-11-12 2023-09-05 安进股份有限公司 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法
TW202300479A (zh) 2021-03-10 2023-01-01 美商安進公司 奧美卡替莫卡必爾之合成
WO2023164452A2 (en) * 2022-02-22 2023-08-31 Yale University Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth
IL319671A (en) 2022-09-26 2025-05-01 Edgewise Therapeutics Inc 4,1-Dihydroquinazolinone compounds and their uses
WO2024081611A1 (en) * 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
JP7858148B1 (ja) 2023-03-27 2026-05-13 エッジワイズ セラピューティクス， インコーポレイテッド キナゾリンジオン化合物およびその使用
EP4688748A1 (en) 2023-03-27 2026-02-11 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
WO2026050494A1 (en) 2024-08-29 2026-03-05 Cytokinetics, Incorporated Omecamtiv mecarbil for use in treating heart failure by activating cardiac sarcomere

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016210240A1 (en) * 2015-06-26 2016-12-29 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
AU2546399A (en) 1998-02-10 1999-08-30 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
EP1551505B1 (en) 2002-10-04 2010-02-24 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
BRPI0512193B8 (pt) 2004-06-17 2021-05-25 Cytokinetics Inc composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal
ES2419007T3 (es) 2005-12-15 2013-08-19 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y procedimientos
WO2007133747A2 (en) 2006-05-15 2007-11-22 Wisconsin Alumni Research Foundation PULMONARY DELIVERY OF 1α,25-DIHYDROXYVITAMIN D3 AND CO-ADMINISTRATION OF PARATHYROID HORMONE OR CALCITONIN
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
EP2139458A4 (en) 2007-04-19 2013-01-23 Dong A Pharm Co Ltd BIODEGRADABLE MICRO BEADS COMPOSITION FOR CONTROLLED RELEASE OF GLUCOSE-CONTROLLED PEPTIDE AND FORMULATION THEREOF
AU2014240049C1 (en) 2013-03-14 2019-03-07 Amgen Inc. Heterocyclic compounds and their uses
AU2014240104B2 (en) * 2013-03-14 2018-11-08 Amgen Inc. Heterocyclic compounds and their uses
CA2975260C (en) 2015-01-29 2024-05-21 Signal Pharmaceuticals Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
US20200087367A1 (en) 2017-02-06 2020-03-19 Acceleron Pharma Inc. Compositions and methods for treating heart failure
LT3645002T (lt) 2017-06-30 2025-02-10 Amgen Inc. Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais
US11040956B2 (en) 2017-06-30 2021-06-22 Amgen Inc. Synthesis of omecamtiv mecarbil
HUE052049T2 (hu) 2018-07-09 2021-04-28 Fis Fabbrica Italiana Sintetici Spa Kristályos 2-fluor-3-nitrotoluol és eljárás annak elõállítására
US11608318B2 (en) 2018-07-12 2023-03-21 Assia Chemical Industries Ltd. Solid state forms of Omecamtiv mecarbil and Omecamtiv mecarbil diHCl
EP3599243B1 (en) 2018-07-26 2023-04-12 CVIE Therapeutics Limited 17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure
JP2021534138A (ja) 2018-08-17 2021-12-09 アムジエン・インコーポレーテツド オメカムチブメカルビルの塩及び結晶形態
WO2020131574A1 (en) 2018-12-18 2020-06-25 Amgen Inc. Method of reducing aromatic nitro compounds
EP3934654B1 (en) 2019-03-05 2026-04-29 Windtree Therapeutics, Inc. Istaroxime or its metabolite pst-3093 for use as intravenous formulation for the treatment of acute heart failure (ahf)
WO2021053189A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021053175A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
EP4041710A1 (en) 2019-10-09 2022-08-17 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
US20220402874A1 (en) 2019-10-09 2022-12-22 Dr. Reddy's Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
CN114945372A (zh) 2019-11-10 2022-08-26 迈奥卡迪亚公司 用肌球蛋白调节剂的治疗方法
GB201918853D0 (en) 2019-12-19 2020-02-05 Lund Lars H Methods of treatment
CN114929671B (zh) 2020-01-03 2024-04-16 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
CA3168513A1 (en) 2020-02-10 2021-08-19 Amgen Inc. Omecamtiv mecarbil tablet
TW202233189A (zh) 2020-11-12 2022-09-01 美商安進公司 藉由投與奧美卡替莫卡必爾治療心臟衰竭之方法
TW202300479A (zh) 2021-03-10 2023-01-01 美商安進公司 奧美卡替莫卡必爾之合成
WO2023205291A2 (en) 2022-04-21 2023-10-26 The Board Of Regents Of The University Of Oklahoma Targeting myocardial tissue for delivery of therapeutic and imaging agents
WO2024081611A1 (en) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) * 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016210240A1 (en) * 2015-06-26 2016-12-29 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Liu CL., et al., "Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure", Expert Opin Investig Drugs, 2016 vol. 25, no. 1, pages 117 - 127 *
Teerlink JR., et al., "Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure The ATOMIC-AHF Study", Jnl Am Co Card, 2016, vol. 67, no. 12, pages 1444 - 1455 *
Teerlink JR., et al., "Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial", Lancet, 2016, vol. 388, no. 10062, pages 2895 - 2903 *

Also Published As

Publication number Publication date
EP4512470A2 (en) 2025-02-26
HRP20241729T1 (hr) 2025-03-14
EP4512470A3 (en) 2025-04-23
CA3068588A1 (en) 2019-01-03
MA49508B1 (fr) 2024-12-31
WO2019006235A1 (en) 2019-01-03
MD3645002T2 (ro) 2025-04-30
PT3645002T (pt) 2025-01-24
US20250255862A1 (en) 2025-08-14
AU2018290983A1 (en) 2020-01-23
BR112019028046A2 (pt) 2020-07-07
JP2023088944A (ja) 2023-06-27
US20230355615A1 (en) 2023-11-09
HUE069805T2 (hu) 2025-04-28
MX2020000190A (es) 2020-07-22
US20230149394A1 (en) 2023-05-18
DK3645002T3 (da) 2024-12-16
SI3645002T1 (sl) 2025-03-31
PL3645002T3 (pl) 2025-03-24
US12295952B2 (en) 2025-05-13
JP2020526483A (ja) 2020-08-31
EP3645002B1 (en) 2024-10-30
JP2025165979A (ja) 2025-11-05
US11576910B2 (en) 2023-02-14
FI3645002T3 (fi) 2025-01-29
SMT202500067T1 (it) 2025-03-12
US11931358B2 (en) 2024-03-19
US20200155547A1 (en) 2020-05-21
MX2022015115A (es) 2023-01-18
ES3008457T3 (en) 2025-03-24
LT3645002T (lt) 2025-02-10
MA49508A (fr) 2020-05-06
AU2024200991A1 (en) 2024-03-07
EP3645002A1 (en) 2020-05-06
CN110996953A (zh) 2020-04-10
RS66581B1 (sr) 2025-04-30
AU2024200991B2 (en) 2025-04-10

Similar Documents

Publication Publication Date Title
AU2024200991B2 (en) Methods of treating heart failure with cardiac sarcomere activators
Sayin et al. Left ventricular hypertrophy: etiology-based therapeutic options
Sezai et al. Feasibility of landiolol and bisoprolol for prevention of atrial fibrillation after coronary artery bypass grafting: a pilot study
JP2024500616A (ja) オメカムチブメカルビルの投与により心不全を処置する方法
EP3411021B1 (en) New use of a combination of sacubitril and valsartan
JP2020520948A (ja) 心不全の治療用のホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）アゴニストの新規な使用
KR20250050043A (ko) 비폐쇄성 비대심근병증 치료 방법
Bernier et al. Cardiac myosin activation for the treatment of systolic heart failure
Cada et al. Sacubitril/valsartan
US20260041679A1 (en) Method of treating hypertension with the aldosterone synthase inhibitor baxdrostat
KR20250056200A (ko) 폐쇄성 비대심장근육병증 치료 방법
HK40028258A (en) Methods of treating heart failure with cardiac sarcomere activators
HK40028258B (en) Methods of treating heart failure with cardiac sarcomere activators
US20240366596A1 (en) Treatment of hfpef in post-menopausal women with an sgc stimulator
HK40027649A (en) Methods of treating heart failure with cardiac sarcomere activators
US20210177803A1 (en) New pharmaceutical use for the treatment of heart failure
Silva Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan
Bozorgnia et al. Current management of heart failure: when to refer to heart failure specialist and when hospice is the best option
Finimundi et al. Effect of diuretic therapy on exercise capacity in patients with chronic angina and preserved left ventricular function
Ahmed et al. Sacubitril/Valsartan: A Novel Approach in the Treatment of Heart Failure with Reduced Ejection Fraction
Mystakidou FACULTY OF HEALTH SCIENCES
Hamdy et al. Why Pillar Directed Therapy Does Not Provide Absolute Protection in Heart Failure? The Five Pillars of the Management of Heart Failure
TW201134818A (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for administration shortly after amiodarone discontinuation

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ HONARPOUR, NARIMON AND MALIK, FADY

FGA Letters patent sealed or granted (standard patent)